|
advertisement
|
|
|
|
| Healthcare IT and Biotechnology News Release |
| News Home :: Healthcare IT and Biotechnology News Releases :: More News Releases on this day |
| Date of Publication: Monday, July 14, 2008 |
Invitrogen to Integrate Brendan Technologies’ Advanced Analytical Software into Protein Analysis Solutions |
| Invitrogen Corporation (NASDAQ:IVGN), a leading provider of essential life sciences technologies for research, production and diagnostics, announced today it has entered into an exclusive agreement with Brendan Technologies (OTCBB:BDTE) to customize its StatLIA® assay analysis software to facilitate the analysis of protein samples. |
CARLSBAD, Calif. -- Invitrogen Corporation (NASDAQ:IVGN), a leading provider of essential life sciences technologies for research, production and diagnostics, announced today it has entered into an exclusive agreement with Brendan Technologies (OTCBB:BDTE) to customize its StatLIA® assay analysis software to facilitate the analysis of protein samples. Financial terms of the agreement were not disclosed.
Brendan’s StatLIA® software allows researchers to quantitate proteins with measurable accuracy and improve assay performance through automated quality control. StatLIA® also helps researchers troubleshoot sample preparation problems using advanced adaptive learning processes. This improves the drug/biomarker discovery, validation and development process with reduced timelines and costs. It will also allow researchers to make better informed judgments about the compatibility of separate data sets.
The software will be designed to work with protein quantitation through mass spectrometry, which is an advanced scientific technique used to analyze compounds based on their molecular composition. For many researchers, it can be a tedious process, often requiring years of advanced study and training to perfect.
“This software maximizes the value of our reagents through state-of-the-art computations and analysis of proteomics mass spectrometry,” said Kip Miller, Invitrogen’s Senior Vice President of BioDiscovery. “This is another example of how Invitrogen is dedicated to helping researchers access powerful, yet complex, technologies through simplifying specific application workflows, such as mass spectrometry. With the pending combination with Applied Biosystems, we will now have greater access to the mass spectrometry customers, allowing us to provide even more solutions addressing their needs.”
“This agreement brings tremendous value to the life science customer by sourcing our software with Invitrogen’s superior technological capabilities,” said John Dunn, PhD, Chief Executive Officer of Brendan Technologies. “Our StatLIA software offers many innovative methodologies to combine advanced computational analysis with the automation, graphical tools, and data visualization needed for today’s life science laboratory. We are looking forward to working with this recognized leader in the global life sciences community.”
|
|
| Other News Items Published on the Monday, July 14, 2008 |
|
|